Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
EARLY PREDICTION MARKERS OF DIABETIC NEPHROPATHY
Document Type and Number:
WIPO Patent Application WO/2016/001215
Kind Code:
A3
Abstract:
The present invention concerns a method for the in vitro detection of an increased risk of diabetic nephropathy in a subject suffering from diabetes and being normoalbuminuric. Another aspect of the invention pertains to a method for the in vitro identification of a marker for prediction of diabetic nephropathy. Finally, the invention concerns a kit comprising means for detecting at least two proteins selected from the group consisting of heparan sulfate proteoglycan core protein or fragments thereof, carbonic anhydrase 1, prothrombin or fragments thereof, tetranectin, CD59 glycoprotein, plasma serine protease inhibitor, mannan-binding lectin serine protease 2 or isoforms thereof, antithrombin-III, alpha-1-antitrypsin, collagen alpha-1(I) chain, alpha-enolase, histone H2B type 1-O, glutaminyl-peptide cyclotransferase, protein AMBP and zinc-alpha-2-glycoprotein.

Inventors:
GRANIER CLAUDE (FR)
MOLINA FRANCK (FR)
SALVETAT NICOLAS (FR)
MOLINA LAURENCE (FR)
SIALA RANDA (BE)
RENARD ERIC (FR)
Application Number:
PCT/EP2015/064831
Publication Date:
February 18, 2016
Filing Date:
June 30, 2015
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
BIO RAD INNOVATIONS (FR)
CENTRE NAT RECH SCIENT (FR)
International Classes:
G01N33/68
Foreign References:
US20120329071A12012-12-27
US20120034240A12012-02-09
Other References:
S. C. LIM ET AL: "Adipocytokine zinc [alpha]2 glycoprotein (ZAG) as a novel urinary biomarker for normo-albuminuric diabetic nephropathy", DIABETIC MEDICINE, vol. 29, no. 7, 19 June 2012 (2012-06-19), pages 945 - 949, XP055147299, ISSN: 0742-3071, DOI: 10.1111/j.1464-5491.2011.03564.x
S. E. NIELSEN ET AL: "Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic Patients", DIABETES CARE, vol. 33, no. 6, 25 February 2010 (2010-02-25), pages 1320 - 1324, XP055147313, ISSN: 0149-5992, DOI: 10.2337/dc09-2242
SOGGIU A ET AL: "A discovery-phase urine proteomics investigation in type 1 diabetes", ACTA DIABETOLOGICA, SPRINGER-VERLAG, MI, vol. 49, no. 6, 8 June 2012 (2012-06-08), pages 453 - 464, XP035144980, ISSN: 1432-5233, DOI: 10.1007/S00592-012-0407-0
ANTONIO LACQUANITI ET AL: ""Normoalbuminuric" diabetic nephropathy: tubular damage and NGAL", ACTA DIABETOLOGICA, vol. 50, no. 6, 11 June 2013 (2013-06-11), pages 935 - 942, XP055147335, ISSN: 0940-5429, DOI: 10.1007/s00592-013-0485-7
RAKOV S S ET AL: "Protein markers of diabetic nephropathy under functional exercise test", KLINICESKAA LABORATORNAA DIAGNOSTIKA, MEDICINA, MOSCOW, RU, no. 2, 1 January 1994 (1994-01-01), pages 24 - 25, XP009180791, ISSN: 0869-2084
O'BRIEN S F ET AL: "Exercise testing as a long-term predictor of the development of microalbuminuria in normoalbuminuric IDDM patients", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, vol. 18, no. 12, 1 December 1995 (1995-12-01), pages 1602 - 1605, XP009180582, ISSN: 0149-5992
KARIN CONDE-KNAPE: "Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications", DIABETES/METABOLISM RESEARCH AND REVIEWS, vol. 17, no. 6, 1 January 2001 (2001-01-01), pages 412 - 421, XP055147364, ISSN: 1520-7552, DOI: 10.1002/dmrr.236
Attorney, Agent or Firm:
BLOT, Philippe et al. (2 place d'Estienne d'Orves, Paris, FR)
Download PDF: